
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly and Co demonstrated strong financial performance across several key segments, with reported organic revenue growth of 8.0% in MedSurgEndoscopy and a notable 16.1% increase in cardiovascular revenues during Q4. The company particularly excelled in electrophysiology, achieving a remarkable 35% organic growth year-over-year, supported by favorable market expansion projections for the sector. Furthermore, neuromodulation revenues increased by 10% and urology revenues grew by 3.0%, reinforcing Eli Lilly's robust positioning and growth trajectory in the pharmaceutical industry.
Bears say
Eli Lilly and Co's stock faced an 18% decline following the company's guidance for 2026, which was perceived as weak, particularly in its electrophysiology (EP) business that failed to meet fourth-quarter consensus expectations. The company is experiencing concerns regarding slower-than-expected uptake of its portfolio and potential pricing pressures, alongside risks related to the performance of its key drug, Mounjaro, in the cardiovascular market. Additionally, the downside scenario outlined suggests higher debt levels and limited operational leverage, casting further doubt on the company's ability to achieve its stated financial goals by 2028.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares